Ferenc Tracik

Dr. Tracik is a physician-leader with more than two decades of expertise in neurological and rare disease drug development. At Neumirna, he will oversee medical and clinical strategy, focusing on patient safety, regulatory interactions, and external medical affairs. He will partner with Neumirna's CDO to guide lead program NMT.001 into the clinic in early 2027 and lend his clinical perspective to Neumirna's preclinical program in Parkinson's disease.

Before joining pharmaceutical industry, Dr. Tracik worked at the university clinics of neurology at Charité Berlin and the university clinic of Innsbruck. Dr. Tracik holds a doctoral degree in human medicine from the Free University of Berlin. More recently, his doctoral research from Universität Regensburg focused on sleep disturbances in Parkinson's disease.

Career History

• Chief Medical Officer, NeuroSense Therapeutics (most recently), where he led global Phase 2 programs in ALS and Alzheimer's disease, including a successful IND submission to the FDA
• Global Head Medical, Orphazyme A/S
• Vice President, Europe, Canada and Partner Markets, Biogen Inc. (May 2017 – November 2020), where he led the European medical launch of an antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA) and established a highly recognized multinational SMA registry
• Various positions at Teva Pharmaceutical Industries Limited (November 2013 – April 2017), including Managing Director Specialty Medicines Germany
• Leadership roles at Novartis

What Dr. Tracik could bring to Chief Medical Officer at Neumirna Therapeutics: Based on his extensive track record, Dr. Tracik brings proven expertise in navigating regulatory pathways for neurological therapies, commercial launch experience with innovative mechanisms like ASO therapies, and deep knowledge of global drug development for neurodegenerative diseases. His success at Biogen in establishing registries and patient access programs, combined with his most recent leadership of Phase 2 clinical programs, positions him to effectively guide Neumirna's pipeline toward clinical development and market readiness.